A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the recommended phase II dose of AVE0005
in combination with S-1 in Japanese cancer patients.
The secondary objectives of this study are to assess the safety profile of AVE0005, to
determine the pharmacokinetics of AVE0005, to make a preliminary assessment of antitumor
effects.